Biogen returns gene therapies to AGTC on lack of clinical activity

Applied Genetic Technologies Corp. (NASDAQ:AGTC) said late Dec. 12 that Biogen Inc. (NASDAQ:BIIB) terminated the companies’ gene therapy collaboration, leaving behind a partnership originally established to help Biogen build its gene therapy expertise. AGTC was down $3.09 (47%) to $3.47 on Dec. 13.

Biogen made the decision to end the partnership after AGTC reported interim

Read the full 549 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE